Calcitonin gene-related peptide triggers migraine-like attacks in patients with migraine with aura JM Hansen, AW Hauge, J Olesen, M Ashina Cephalalgia 30 (10), 1179-1186, 2010 | 518 | 2010 |
Guidelines for controlled trials of drugs in migraine: A guide for investigators International Headache Society Clinical Trials Subcommittee members:, ... Cephalalgia 32 (1), 6-38, 2012 | 399 | 2012 |
Migraine and the trigeminovascular system—40 years and counting M Ashina, JM Hansen, TP Do, A Melo-Carrillo, R Burstein, MA Moskowitz The Lancet Neurology 18 (8), 795-804, 2019 | 396 | 2019 |
Red and orange flags for secondary headaches in clinical practice: SNNOOP10 list TP Do, A Remmers, HW Schytz, C Schankin, SE Nelson, M Obermann, ... Neurology 92 (3), 134-144, 2019 | 330 | 2019 |
Vasoactive intestinal peptide causes marked cephalic vasodilation, but does not induce migraine A Rahmann, T Wienecke, JM Hansen, J Fahrenkrug, J Olesen, M Ashina Cephalalgia 28 (3), 226-236, 2008 | 306 | 2008 |
Human models of migraine—short-term pain for long-term gain M Ashina, JM Hansen, BO á Dunga, J Olesen Nature Reviews Neurology 13 (12), 713-724, 2017 | 206 | 2017 |
Migraine headache is present in the aura phase: a prospective study JM Hansen, RB Lipton, DW Dodick, SD Silberstein, JR Saper, SK Aurora, ... Neurology 79 (20), 2044-2049, 2012 | 155 | 2012 |
Intravenous alteplase for stroke with unknown time of onset guided by advanced imaging: systematic review and meta-analysis of individual patient data G Thomalla, F Boutitie, H Ma, M Koga, P Ringleb, LH Schwamm, O Wu, ... The Lancet 396 (10262), 1574-1584, 2020 | 149 | 2020 |
Opening of ATP-sensitive potassium channels causes migraine attacks: a new target for the treatment of migraine MAM Al-Karagholi, JM Hansen, S Guo, J Olesen, M Ashina Brain 142 (9), 2644-2654, 2019 | 118 | 2019 |
Pearls and pitfalls in human pharmacological models of migraine: 30 years' experience M Ashina, JM Hansen, J Olesen Cephalalgia 33 (8), 540-553, 2013 | 116 | 2013 |
Vasoactive intestinal polypeptide evokes only a minimal headache in healthy volunteers JM Hansen, J Sitarz, S Birk, AM Rahmann, PS Oturai, J Fahrenkrug, ... Cephalalgia 26 (8), 992-1003, 2006 | 116 | 2006 |
Distinctive anatomical and physiological features of migraine aura revealed by 18 years of recording JM Hansen, SM Baca, P VanValkenburgh, A Charles Brain 136 (12), 3589-3595, 2013 | 111 | 2013 |
Variability of clinical features in attacks of migraine with aura JM Hansen, PJ Goadsby, AC Charles Cephalalgia 36 (3), 216-224, 2016 | 96 | 2016 |
Functional connectivity studies in migraine: what have we learned? K Skorobogatykh, WS Van Hoogstraten, D Degan, A Prischepa, ... The journal of headache and pain 20, 1-10, 2019 | 92 | 2019 |
Calcitonin gene–related peptide does not cause the familial hemiplegic migraine phenotype JM Hansen, LL Thomsen, J Olesen, M Ashina Neurology 71 (11), 841-847, 2008 | 81 | 2008 |
Differences in treatment response between migraine with aura and migraine without aura: lessons from clinical practice and RCTs JM Hansen, A Charles The journal of headache and pain 20 (1), 96, 2019 | 75 | 2019 |
Familial hemiplegic migraine type 1 shows no hypersensitivity to nitric oxide JM Hansen, LL Thomsen, J Olesen, M Ashina Cephalalgia 28 (5), 496-505, 2008 | 75 | 2008 |
Migraine aura: new ideas about cause, classification, and clinical significance A Charles, JM Hansen Current Opinion in Neurology 28 (3), 255-260, 2015 | 66 | 2015 |
Familial hemiplegic migraine type 2 does not share hypersensitivity to nitric oxide with common types of migraine JM Hansen, LL Thomsen, R Marconi, G Casari, J Olesen, M Ashina Cephalalgia 28 (4), 367-375, 2008 | 66 | 2008 |
Dose‐response testing with nickel sulphate using the TRUE test® in nickel‐sensitive individuals. Multiple nickel sulphate patch‐test reactions do not cause an “angry back” KE Andersen, C Liden, J Hansen, A Vøeund British Journal of Dermatology 129 (1), 50-56, 1993 | 65 | 1993 |